Spiruchostatin A is a Potent HDAC Inhibitor with anticancer activity
2022-12-02
Histone deacetylase (HDAC) is an enzyme that catalyzes the removal of acetyl functional groups from the lysine residues of histones and non-histones. Among other things, histone lysine acetylation is highly reversible. HDAC-catalyzed epigenetic modification of histone acetylation regulates chromatin structure and transcription, while non-histone deacetylation controls a variety of cellular processes. Also, HDAC is affected by multiple control mechanisms, including protein-protein interactions and post-translational modifications. Aberrant HDAC plays a key role in many human diseases. HDAC inhibitors are currently known to be potential anticancer agents and show promise for the treatment of many diseases.
Keywords
Apoptosis | cancer | HDAC | Histone deacetylase | leukemia
References



